Caseware UK (AP4) 2023.0.135 2023.0.135 2023-11-302023-11-30truefalsefalse2022-11-14No description of principal activity2trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 14484240 2022-11-13 14484240 2022-11-14 2023-11-30 14484240 2021-11-14 2022-11-13 14484240 2023-11-30 14484240 c:Director1 2022-11-14 2023-11-30 14484240 d:ComputerEquipment 2022-11-14 2023-11-30 14484240 d:ComputerEquipment 2023-11-30 14484240 d:ComputerEquipment d:OwnedOrFreeholdAssets 2022-11-14 2023-11-30 14484240 d:DevelopmentCostsCapitalisedDevelopmentExpenditure 2023-11-30 14484240 d:CurrentFinancialInstruments 2023-11-30 14484240 d:CurrentFinancialInstruments d:WithinOneYear 2023-11-30 14484240 d:ShareCapital 2023-11-30 14484240 d:SharePremium 2023-11-30 14484240 d:RetainedEarningsAccumulatedLosses 2023-11-30 14484240 c:FRS102 2022-11-14 2023-11-30 14484240 c:AuditExempt-NoAccountantsReport 2022-11-14 2023-11-30 14484240 c:FullAccounts 2022-11-14 2023-11-30 14484240 c:PrivateLimitedCompanyLtd 2022-11-14 2023-11-30 14484240 d:DevelopmentCostsCapitalisedDevelopmentExpenditure d:ExternallyAcquiredIntangibleAssets 2022-11-14 2023-11-30 14484240 e:PoundSterling 2022-11-14 2023-11-30 iso4217:GBP xbrli:pure

Registered number: 14484240









EVELYN HEALTH LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE PERIOD ENDED 30 NOVEMBER 2023

 
EVELYN HEALTH LIMITED
REGISTERED NUMBER: 14484240

BALANCE SHEET
AS AT 30 NOVEMBER 2023

2023
2023
Note
£
£

Fixed assets
  

Intangible assets
 4 
13,548

Tangible assets
 5 
738

  
14,286

Current assets
  

Debtors: amounts falling due within one year
 6 
3,658

Cash at bank and in hand
 7 
11,480

  
15,138

Creditors: amounts falling due within one year
 8 
(209,418)

Net current liabilities
  
 
 
(194,280)

Total assets less current liabilities
  
(179,994)

  

Net liabilities
  
(179,994)


Capital and reserves
  

Called up share capital 
  
1

Share premium account
  
21,999

Profit and loss account
  
(201,994)

  
(179,994)


Page 1

 
EVELYN HEALTH LIMITED
REGISTERED NUMBER: 14484240
    
BALANCE SHEET (CONTINUED)
AS AT 30 NOVEMBER 2023

The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




J Williams
Director

Date: 12 August 2024

The notes on pages 3 to 7 form part of these financial statements.

Page 2

 
EVELYN HEALTH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 NOVEMBER 2023

1.


General information

Evelyn Health Limited is a private company limited by shares. The company is incorporated in England and Wales and its registered address is 124 City Road, London, EC1V 2NX.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

 
2.3

Government grants

Grants are accounted under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to profit or loss at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income.
Grants of a revenue nature are recognised in the Statement of Income and Retained Earnings in the same period as the related expenditure.

 
2.4

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

Page 3

 
EVELYN HEALTH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 NOVEMBER 2023

2.Accounting policies (continued)

 
2.5

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

 
2.6

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Computer equipment
-
3 years straight-line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.7

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.8

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.9

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 4

 
EVELYN HEALTH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 NOVEMBER 2023

2.Accounting policies (continued)

 
2.10

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Basic financial assets

Basic financial assets, which include trade and other receivables, cash and bank balances, are initially measured at their transaction price including transaction costs and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other receivables due with the operating cycle fall into this category of financial instruments.

Financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instruments any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other payables, bank loans and other loans are initially measured at their transaction price after transaction costs. When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade payables are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade payables are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade payables are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.


3.


Employees

The average monthly number of employees, including directors, during the period was 2.

Page 5

 
EVELYN HEALTH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 NOVEMBER 2023

4.


Intangible assets



Website

£



Cost


Additions
13,548



At 30 November 2023

13,548






Net book value



At 30 November 2023
13,548




5.


Tangible fixed assets





Computer equipment

£



Cost or valuation


Additions
1,022



At 30 November 2023

1,022



Depreciation


Charge for the period on owned assets
284



At 30 November 2023

284



Net book value



At 30 November 2023
738

Page 6

 
EVELYN HEALTH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 NOVEMBER 2023

6.


Debtors

2023
£


Other debtors
3,658



7.


Cash and cash equivalents

2023
£

Cash at bank and in hand
11,480



8.


Creditors: Amounts falling due within one year

2023
£

Trade creditors
1,200

Other creditors
206,718

Accruals and deferred income
1,500

209,418


 
Page 7